AZD9150 treatment caused knockdown of STAT3 expression in AML cell lines and human primary myelodysplastic syndrome (MDS)/AML stem cells [68], resulting in an increase in erythroid and myeloid differentiated colonies. The gene discussed is STAT3; the disease is acute myeloid leukemia.